Work­ing like a ma­chine dur­ing the pan­dem­ic, MO­MA taps in­vestors to bankroll its 'mol­e­c­u­lar ma­chi­nes'

For a biotech that opened its lab the week be­fore the pan­dem­ic shut­tered many of­fices, MO­MA Ther­a­peu­tics has ex­pe­ri­enced hard­ly a blip in op­er­a­tions, so much so that it at­tract­ed 15-year Take­da vet Asit Parikh last year as CEO and — amid a wilt­ing fi­nanc­ing en­vi­ron­ment — a $150 mil­lion Se­ries B to take on the ma­chine.

So-called mol­e­c­u­lar ma­chines, that is. The Third Rock Ven­tures-in­cu­bat­ed start­up will use the pro­ceeds to bankroll con­tin­ued work on the class of en­zymes that “gen­er­ate force and mo­tion with­in cells,” Parikh told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER